Recurrent CLTC::SYK Fusions and CSF1R Mutations in Juvenile Xanthogranuloma of Soft Tissue

Research on Juvenile Xanthogranuloma Reveals Novel Genetic Mutations Juvenile xanthogranuloma (JXG), a rare histiocytic neoplasm, typically manifests in the skin but occasionally presents extracutaneously in locations such as soft tissue or the central nervous system (CNS). The genetic drivers underlying these extracutaneous variants remain poorly ...

RBM39 as a Therapeutic Target in Acute Lymphoblastic Leukemia: Disruption of Cotranscriptional Splicing

Research Summary Potential of Targeting RBM39 in High-Risk Acute Lymphoblastic Leukemia (B-ALL) Background Overview Acute Lymphoblastic Leukemia (ALL) is a hematological malignancy commonly diagnosed in children and young adults. Despite high remission rates through frontline chemotherapies, the long-term survival rate for patients with relapsed/re...

Clonal Landscape and Clinical Outcomes of Telomere Biology Disorders: Somatic Rescue and Cancer Mutations

Report on the Academic Paper: Clonal Landscape and Clinical Outcomes of Telomere Biology Disorders: Somatic Rescue and Cancer Mutations Academic Background and Research Motivation Telomere biology disorders (TBDs) are a group of diseases caused by pathogenic germline variants (PGVs) in telomere-related genes, manifesting with multi-organ dysfunctio...

Ide-cel vs Standard Regimens in Triple-Class–Exposed Relapsed and Refractory Multiple Myeloma: Updated KARMMA-3 Analyses

Latest Research Report: Idecabtagene Vicleucel (ide-cel) Significantly Extends Progression-Free Survival in Triple-Class Exposed (TCE) Relapsed or Refractory Multiple Myeloma – Results from the KARMMA-3 Clinical Trial Academic Background and Research Question Patients with Multiple Myeloma (MM) often relapse after multiple lines of therapy, with pr...

Efficacy and Safety of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma

Interpretation of Research on the Efficacy and Safety of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma Following Anti-BCMA Therapies Academic Background Multiple myeloma (MM) is a malignancy stemming from plasma cells within the bone marrow. Recent advancements in treatment have significantly improved overall survival rates. How...

Focal Deletions of a Promoter Tether Activate the IRX3 Oncogene in T-Cell Acute Lymphoblastic Leukemia

Stage-specific Chromosomal Deletions Activate the IRX3 Oncogene in T-cell Acute Lymphoblastic Leukemia In the field of cancer research, understanding regulatory mechanisms of the noncoding genome remains a key focus, especially concerning how oncogenes can be aberrantly activated through non-canonical regulatory pathways. This paper, authored by Su...